Could improving sleep boost a soldier’s recovery from post-traumatic stress disorder?

New York drug maker Tonix Pharma seems to think so; it’s testing a long-approved muscle relaxant, cyclopenzaprine, as a way to help calm the brain before sleep to subdue PTSD symptoms. The company just got breakthrough designation from the Food and Drug Administration, and will be entering Phase 3 trials in patients with military-related PTSD in the first quarter of 2017.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The approval of cyclobenzaprine as a “breakthrough” simply shows how far we have to go in developing more meaningful pharmacologic treatments for PTSD.

  • Wonder what it will cost, considering cyclobenzaprine (Flexiril) costs about 11 cents a pill. Any studies showing the sublingual form is any better? PS: Amitriptyline and nortriptylline have similar chemical structures.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy